Works matching IS 22113428 AND DT 2023 AND VI 46 AND IP 1

Results: 16

Retraction Note: The POU2F1/miR-4490/USP22 axis regulates cell proliferation and metastasis in gastric cancer.

Published in:

2023

By:

Xiao, Yizhi;
Liu, Side;
Li, Jiaying;
Dai, Weiyu;
Tang, Weimei;
Xiang, Li;
Zhang, Wenjing;
Lin, Jianjiao;
Wang, Jing;
Wu, Xiaosheng;
Liu, Guangnan;
Liu, Yuyang;
Chen, Yaying;
Zhu, Huiqiong;
Wang, Yusi;
Lin, Zhizhao;
Yang, Qiong;
Chen, Tianming;
Sun, Yong;
Li, Aimin

Publication type:

Correction Notice

Correction to: IDH2, a novel target of OGT, facilitates glucose uptake and cellular bioenergy production via NF-κB signaling to promote colorectal cancer progression.

Published in:

2023

By:

He, Xiaoli;
Wu, Nan;
Li, Renlong;
Zhang, Haohao;
Zhao, Yu;
Nie, Yongzhan;
Wu, Jing

Publication type:

Correction Notice

PD-1-CD28 fusion protein strengthens mesothelin-specific TRuC T cells in preclinical solid tumor models.

Published in:

Cellular Oncology (2211-3428), 2023, v. 46, n. 1, p. 227, doi. 10.1007/s13402-022-00747-9

By:

Lesch, Stefanie;
Nottebrock, Alessia;
Rataj, Felicitas;
Heise, Constanze;
Endres, Stefan;
Kobold, Sebastian

Publication type:

Article

Single cell profiling of γδ hepatosplenic T-cell lymphoma unravels tumor cell heterogeneity associated with disease progression.

Published in:

Cellular Oncology (2211-3428), 2023, v. 46, n. 1, p. 211, doi. 10.1007/s13402-022-00745-x

By:

Song, Wei;
Zhang, Haixi;
Yang, Fan;
Nakahira, Kiichi;
Wang, Cheng;
Shi, Keqian;
Zhang, Ruoyu

Publication type:

Article

PKMYT1 inhibits lung adenocarcinoma progression by abrogating AKT1 activity.

Published in:

Cellular Oncology (2211-3428), 2023, v. 46, n. 1, p. 195, doi. 10.1007/s13402-022-00744-y

By:

Wang, Shuang;
Liu, Ximeng;
Zhou, Ting;
Li, Jinling;
Lin, Ying;
Zhou, Anni;
Huang, Jiamin;
Zhao, Jingjing;
Cai, Junchao;
Cai, Xiuyu;
Huang, Yongbo;
Li, Xu

Publication type:

Article

Kavain ablates the radio-resistance of IDH-wildtype glioblastoma by targeting LITAF/NF-κB pathway.

Published in:

Cellular Oncology (2211-3428), 2023, v. 46, n. 1, p. 179, doi. 10.1007/s13402-022-00743-z

By:

Yu, Jianzhong;
Shi, Jun;
Yuan, Fang;
Yin, Wenhao;
Zeng, Hui;
Ge, Lin;
Li, Hao;
Wang, Xiongwei

Publication type:

Article

TNFR2 antagonistic antibody induces the death of tumor infiltrating CD4+Foxp3+ regulatory T cells.

Published in:

Cellular Oncology (2211-3428), 2023, v. 46, n. 1, p. 167, doi. 10.1007/s13402-022-00742-0

By:

He, Tianzhen;
Chen, Yibo;
Yang, De;
Islam, Md Sahidul;
Chou, Chon-Kit;
Liu, Jiarui;
Faustman, Denise L.;
Oppenheim, Joost J.;
Chen, Xin

Publication type:

Article

Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment.

Published in:

Cellular Oncology (2211-3428), 2023, v. 46, n. 1, p. 17, doi. 10.1007/s13402-022-00741-1

By:

Zhu, Yu-Heng;
Zheng, Jia-Hao;
Jia, Qin-Yuan;
Duan, Zong-Hao;
Yao, Hong-Fei;
Yang, Jian;
Sun, Yong-Wei;
Jiang, Shu-Heng;
Liu, De-Jun;
Huo, Yan-Miao

Publication type:

Article

IDH2, a novel target of OGT, facilitates glucose uptake and cellular bioenergy production via NF-κB signaling to promote colorectal cancer progression.

Published in:

Cellular Oncology (2211-3428), 2023, v. 46, n. 1, p. 145, doi. 10.1007/s13402-022-00740-2

By:

He, Xiaoli;
Wu, Nan;
Li, Renlong;
Zhang, Haohao;
Zhao, Yu;
Nie, Yongzhan;
Wu, Jing

Publication type:

Article

Targeting ARHGEF12 promotes neuroblastoma differentiation, MYCN degradation, and reduces tumorigenicity.

Published in:

Cellular Oncology (2211-3428), 2023, v. 46, n. 1, p. 133, doi. 10.1007/s13402-022-00739-9

By:

Yang, Yi;
Wang, Siqi;
Cai, Jiaoyang;
Liang, Jianwei;
Zhang, Yingwen;
Xie, Yangyang;
Luo, Fei;
Tang, Jingyan;
Gao, Yijin;
Shen, Shuhong;
Feng, Haizhong;
Li, Yanxin

Publication type:

Article

AKT-driven epithelial-mesenchymal transition is affected by copper bioavailability in HER2 negative breast cancer cells via a LOXL2-independent mechanism.

Published in:

Cellular Oncology (2211-3428), 2023, v. 46, n. 1, p. 93, doi. 10.1007/s13402-022-00738-w

By:

Vitaliti, Alessandra;
Roccatani, Ilenia;
Iorio, Egidio;
Perta, Nunzio;
Gismondi, Angelo;
Chirico, Mattea;
Pisanu, Maria Elena;
Di Marino, Daniele;
Canini, Antonella;
De Luca, Anastasia;
Rossi, Luisa

Publication type:

Article

Dual anti-angiogenic and anti-metastatic activity of myriocin synergistically enhances the anti-tumor activity of cisplatin.

Published in:

Cellular Oncology (2211-3428), 2023, v. 46, n. 1, p. 117, doi. 10.1007/s13402-022-00737-x

By:

Jeong, Ji-Hak;
Ojha, Uttam;
Jang, Hyeonha;
Kang, Soohyun;
Lee, Sunhee;
Lee, You Mie

Publication type:

Article

FUT8 is regulated by miR‐122‐5p and promotes malignancies in intrahepatic cholangiocarcinoma via PI3K/AKT signaling.

Published in:

Cellular Oncology (2211-3428), 2023, v. 46, n. 1, p. 79, doi. 10.1007/s13402-022-00736-y

By:

Chen, Fanghua;
Li, Yin;
Aye, Ling;
Wu, Yingcheng;
Dong, Liangqing;
Yang, Zijian;
Gao, Qiang;
Zhang, Shu

Publication type:

Article

CoQ10 reduces glioblastoma growth and infiltration through proteome remodeling and inhibition of angiogenesis and inflammation.

Published in:

Cellular Oncology (2211-3428), 2023, v. 46, n. 1, p. 65, doi. 10.1007/s13402-022-00734-0

By:

Frontiñán-Rubio, Javier;
Llanos-González, Emilio;
García-Carpintero, Sonia;
Peinado, Juan Ramón;
Ballesteros-Yáñez, Inmaculada;
Rayo, Margarita Villar;
de la Fuente, José;
Pérez-García, Víctor M.;
Perez-Romasanta, Luis A.;
Malumbres, Marcos;
Alcaín, Francisco J.;
Durán-Prado, Mario

Publication type:

Article

In vivo study revealed pro-tumorigenic effect of CMTM3 in hepatocellular carcinoma involving the regulation of peroxisome proliferator-activated receptor gamma (PPARγ).

Published in:

Cellular Oncology (2211-3428), 2023, v. 46, n. 1, p. 49, doi. 10.1007/s13402-022-00733-1

By:

Wang, Jiahui;
Chu, Hongjin;
Wang, Zhixin;
Wang, Xuebo;
Liu, Xuexia;
Song, Zhan;
Liu, Fujun

Publication type:

Article

Research advances and treatment perspectives of pancreatic adenosquamous carcinoma.

Published in:

Cellular Oncology (2211-3428), 2023, v. 46, n. 1, p. 1, doi. 10.1007/s13402-022-00732-2

By:

Zhang, Wen;
Zhang, Jing;
Liang, Xijun;
Ding, Jin

Publication type:

Article

Works matching IS 22113428 AND DT 2023 AND VI 46 AND IP 1

Retraction Note: The POU2F1/miR-4490/USP22 axis regulates cell proliferation and metastasis in gastric cancer.

Correction to: IDH2, a novel target of OGT, facilitates glucose uptake and cellular bioenergy production via NF-κB signaling to promote colorectal cancer progression.

PD-1-CD28 fusion protein strengthens mesothelin-specific TRuC T cells in preclinical solid tumor models.

Single cell profiling of γδ hepatosplenic T-cell lymphoma unravels tumor cell heterogeneity associated with disease progression.

PKMYT1 inhibits lung adenocarcinoma progression by abrogating AKT1 activity.

Kavain ablates the radio-resistance of IDH-wildtype glioblastoma by targeting LITAF/NF-κB pathway.

TNFR2 antagonistic antibody induces the death of tumor infiltrating CD4<sup>+</sup>Foxp3<sup>+</sup> regulatory T cells.

Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment.

IDH2, a novel target of OGT, facilitates glucose uptake and cellular bioenergy production via NF-κB signaling to promote colorectal cancer progression.

Targeting ARHGEF12 promotes neuroblastoma differentiation, MYCN degradation, and reduces tumorigenicity.

AKT-driven epithelial-mesenchymal transition is affected by copper bioavailability in HER2 negative breast cancer cells via a LOXL2-independent mechanism.

Dual anti-angiogenic and anti-metastatic activity of myriocin synergistically enhances the anti-tumor activity of cisplatin.

FUT8 is regulated by miR‐122‐5p and promotes malignancies in intrahepatic cholangiocarcinoma via PI3K/AKT signaling.

CoQ<sub>10</sub> reduces glioblastoma growth and infiltration through proteome remodeling and inhibition of angiogenesis and inflammation.

In vivo study revealed pro-tumorigenic effect of CMTM3 in hepatocellular carcinoma involving the regulation of peroxisome proliferator-activated receptor gamma (PPARγ).

Research advances and treatment perspectives of pancreatic adenosquamous carcinoma.